UK-based ProStrakan opens US headquarters
His Royal Highness, The Duke of York, was the guest of honor at a lunch held to mark the US launch of the UK-based specialty pharmaceutical company ProStrakan Group plc.
NEW YORK-His Royal Highness, The Duke of York, was the guest of honor at a lunch held to mark the US launch of the UK-based specialty pharmaceutical company ProStrakan Group plc. The company’s new US headquarters are in Bedminster, New Jersey. Prince Andrew is visiting the US as the UK’s Special Representative for International Trade & Investment. He accepted the lunch invitation after visiting ProStrakan’s headquarters in Galashiels, Scotland, last year.
ProStrakan’s first US product, Sancuso, is currently under consideration by the FDA. Sancuso is a transdermal patch that delivers granisetron, an established 5-HT3 receptor antagonist, steadily into the bloodstream over a number of days, helping to prevent the side effects of nausea and vomiting in patients undergoing chemotherapy without the need for injection or having to swallow pills.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
